See how your answers relate to your colleagues'.


The PROMISE study, published in Diabetes Technology & Therapeutics in February 2022, was completed in order to evaluate:
a. Accuracy and safety of a next generation 90-day CGM system
b. Accuracy and safety of the next-generation implantable CGM system for up to 180 days
c. People with diabetes' need of an implantable CGM system for up to 180 days
d. None of the above

Submit
cgmEDUCATION.net is supported by independent educational grants from Insulet Corporation, Madrigal Pharmaceuticals, MannKind Corporation, Medtronic, Stanford University, and Tandem Diabetes Care, Inc.
©2024 CogniMed Inc. All rights reserved.